Search Results
Your search for ,WHo matches 20933 pages
Showing 20451 - 20500Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rate in Initial Therapy for Follicular Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Illidge et al evaluated radioimmunotherapy with fractionated 90Y-ibritumomab tiuxetan (Zevalin) as initial treatment in patients with mostly advanced follicular lymphoma. The treatment was well tolerated, with manageable...
Less Is More: Postoperative Radiation May Be Avoided in Older Women With Estrogen Receptor–Rich Tumors
Among older women with hormone receptor–positive breast cancer, it is reasonable to omit whole-breast radiation therapy after breast-conserving surgery and neoadjuvant hormone therapy if the patient’s tumors have high levels of estrogen receptor expression, but radiation should remain...
NeoALTTO Trial Links Pathologic Complete Response to Clinical Outcomes
Final results of the phase III NeoALTTO trial have confirmed the value of pathologic complete response to dual HER2 blockade in the neoadjuvant setting. The achievement of pathologic complete response was associated with significantly improved event-free survival and overall survival in some women...
Addition of Bevacizumab Fails to Improve Invasive Disease-Free Survival vs Adjuvant Chemotherapy/Trastuzumab Alone in HER2-Positive Breast Cancer
Bevacizumab (Avastin) failed to extend invasive disease–free survival when added to trastuzumab (Herceptin)-directed adjuvant chemotherapy in patients with HER2-positive breast cancer in the phase III BETH trial. Although not specifically designed to answer this question, BETH also...
Benefit of Breast Cancer Screening More Consistent Across Studies Than Previously Understood
Re-examination of data from four large studies of the benefits and harms of mammography screening shows that the benefits are more consistent across these studies than previously understood and that all the studies indicate a substantial reduction in breast cancer mortality with screening,...
High Levels of Immune Cells in Tumors May Identify Breast Cancer Patients Most Likely to Benefit From Trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab (Herceptin), according to results presented today at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-05)....
ASH 2013: Brentuximab Vedotin Shows Promising Activity in Non-Hodgkin Lymphoma
The antibody-drug conjugate brentuximab vedotin (Adcetris) has shown “compelling” antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, in a study presented at the American Society of Hematology (ASH) Annual Meeting and Exposition...
Study Explores Risk of New Primary Melanomas After Diagnosis of Stage III/IV Melanoma in Patients Not Receiving BRAF Inhibitors
In a study reported in the Journal of Clinical Oncology, Zimmer et al assessed the incidence of spontaneous new primary melanomas in patients with stage III or IV melanoma in order to help clarify risk of BRAF inhibitor–related new melanomas. They found that patients not receiving BRAF...
Elevated Plasma Vitamin B12 Levels Associated With Cancer Risk
High plasma levels of vitamin B12 (cobalamin) have been reported in patients with cancer of different types. In a Danish study reported in the Journal of the National Cancer Institute, Arendt et al assessed cancer risk in subjects presenting with elevated cobalamin. They found that cancer risk...
Biologic Doublet a Potential Front-Line Treatment in Mantle Cell Lymphoma
A high proportion of mantle cell lymphoma patients may achieve an objective and durable response to treatment with an initial chemotherapy-free regimen, according to Jia Ruan, MD, PhD, of Weill Cornell Medical College, New York, who presented the results of a multicenter phase II study at the 55th...
Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival
A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...
Continuous Lenalidomide/Low-Dose Dexamethasone Improves Survival vs Standard Treatment in Older Patients With Newly Diagnosed Myeloma
First-line treatment of newly diagnosed multiple myeloma using continuous treatment with the doublet of lenalidomide (Revlimid) and low-dose dexamethasone was superior to standard triplet treatment with melphalan, prednisone, and thalidomide (Thalomid) for 72 weeks, according to initial results of...
Gemtuzumab Ozogamicin Reduces Relapse, Improves Event-Free Survival in Pediatric AML
The monoclonal antibody gemtuzumab ozogamicin (Mylotarg) improved event-free survival and reduced the risk of relapse in children with acute myeloid leukemia (AML) in a study from the Children’s Oncology Group, presented at the 55th American Society of Hematology (ASH) Annual Meeting and...
Long-Term Symptoms Beyond 10 Years Experienced by Prostate Cancer Survivors
Years after receiving treatment, many patients who survive prostate cancer continue to experience treatment-related symptoms, according to the findings of a study by Darwish-Yassine et al published in the Journal of Cancer Survivorship. These findings highlight the need for improvements in survivor ...
Reduced-Intensity Hematopoietic Stem Cell Transplant Spares Cognition
The intensity of transplant-related chemotherapy and radiation has effects on cognition, according to a study presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 913). Full-intensity hematopoietic stem cell transplant was associated with cognitive...
Successful Chimeric Antigen Receptor–Expressing T-Cell Treatment Reported in Advanced Lymphomas
Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...
Graft Manipulation Improves HLA-Haploidentical Hematopoietic Stem Cell Transplant Outcomes
T-cell–depleted HLA-haploidentical hematopoietic stem cell transplantation can be made more efficacious and safer through the removal of alpha/beta-positive T cells and CD19-positive B cells from the graft, an approach pioneered by Italian investigators who reported results at the 55th...
Vorinostat Plus Standard Immunoprophylaxis Cuts Risk of Graft-vs-Host Disease in Half
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of bone marrow transplant treatments, according to a study by Choi et al published in The Lancet Oncology. The study, the first to test this treatment in humans, combined the drug vorinostat...
Reduced Renal Function Observed in Patients Taking Crizotinib for Non‒Small Cell Lung Cancer
Patients receiving crizotinib (Xalkori) for the treatment of anaplastic lymphoma kinase (ALK)-positive non?small cell lung cancer (NSCLC) had reductions in their estimated glomerular filtration rate, according to the findings of a study by Brosnan et al published in the journal Cancer. In the...
Genetic Mutation May Play a Role in Worse Outcomes for Obese Prostate Cancer Patients
A study by researchers from Harvard School of Public Health, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital has found that overweight or obese men with prostate cancer whose tumors were positive for the TMPRSS2:ERG genetic mutation had more than a 50% increased risk of dying...
PPM1D Mutations in Circulating White Blood Cells Associated With Risk of Ovarian Cancer, Increased Mortality, and Risk of Breast Cancer
In a brief communication published in the Journal of the National Cancer Institute, Akbari et al reported finding a higher frequency of PPM1D mutations in circulating white blood cells from women with ovarian cancer vs controls, higher mortality associated with the mutation in women with ovarian...
Nonsignificant Survival Benefit With Postoperative Radiation Therapy for Head and Neck Cancer at Academic Center vs Other Institutions
In a study reported in JAMA Otolaryngology Head & Neck Surgery, George et al evaluated radiation treatment characteristics and outcomes among head and neck squamous cell carcinoma patients receiving adjuvant external-beam radiation therapy at an academic center vs other institutions....
Digital Breast Tomosynthesis Increases Cancer Detection and Reduces Recall Rates
Compared to traditional mammography, three-dimensional (3D) mammography—known as digital breast tomosynthesis—found 22% more breast cancers and led to fewer call-backs in a large screening study at the Hospital of the University of Pennsylvania, researchers reported today at the 99th...
Maintained Oral Intake and Swallowing Exercise Adherence During Radiation Therapy Improve Long-Term Swallowing Outcomes for Pharyngeal Cancer Patients
In a study reported in JAMA Otolaryngology Head & Neck Surgery, Hutcheson et al assessed the effects of maintained oral intake and adherence to swallowing exercises during radiation therapy or chemoradiation therapy for pharyngeal cancer. They found that both practices contributed independently ...
Nurse Navigators Improve Patient-Reported Quality of Care in Early Cancer Care
In a study reported in the Journal of Clinical Oncology, Wagner et al assessed whether a nurse navigator intervention improved quality of life or patient experience with care in patients who recently received a diagnosis of breast, colorectal, or lung cancer. Although no differences in...
Postradiotherapy Neck Dissection Improves Local Control in Head and Neck Squamous Cell Carcinoma Patients With Advanced Nodal Disease
Available data indicate that lymph node involvement predicts failure at primary and distant sites after chemoradiation for head and neck cancer. In a study reported in JAMA Otolaryngology Head & Neck Surgery, Ranck et al assessed the impact of postradiotherapy neck dissection on local and...
Three-Drug Regimen Produces High Response Rate in Relapsed/Refractory Multiple Myeloma
A phase II trial to evaluate the combination of bendamustine (Treanda) with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma “showed a remarkable response rate of 60.9%, and, when minor responses were included in 75.9% of patients,”...
Over-Regulation of Opioids Is Resulting in Untreated Cancer Pain for Millions of Patients Worldwide
The results from the European Society for Medical Oncology (ESMO)-led Global Opioid Policy Initiative (GOPI) project show that due to a lack of access to essential opioids, more than 4 billion people—over half the world’s population—live in countries where regulatory barriers,...
U.S. Preventive Services Task Force Issues Final Recommendations on Screening for Oral Cancer
The U.S. Preventive Services Task Force (USPSTF) today released its final recommendation statement on screening for oral cancer in adults without signs or symptoms of oral cancer who are seen by primary care providers. This recommendation focuses on primary care professionals and is not a...
Low-Fat Diet and Fish Oil Supplementation Reduces Cell-Cycle Progression in Prostate Cancer
In a post hoc analysis reported in the journal Cancer Prevention Research, Galet et al analyzed the effects of diet on men with prostate cancer. They found that men who were on a low-fat diet and fish oil supplementation had lower cell-cycle progression scores, which are associated with less...
Thyroid Ultrasound Strategy Identifies Low-Risk Patients Who Can Defer Biopsy
In a study reported in JAMA Internal Medicine, Smith-Bindman et al evaluated the ability of ultrasound imaging characteristics to determine risk of thyroid cancer associated with thyroid nodules. They found that a strategy of using two abnormal nodule characteristics as an indication for biopsy...
Certain Symptom Clusters After Surgery for Esophageal Cancer Predict Poor Prognosis
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease. The findings by Wikman et al were published...
ASCO Endorses Cancer Care Ontario Guideline for Follow-up in Colorectal Cancer Survivors
ASCO has policy and procedures for endorsing clinical practice guidelines developed by other professional organizations. As reported in the Journal of Clinical Oncology by Meyerhardt et al of the ASCO Clinical Practice Guidelines Committee, ASCO has endorsed the Cancer Care Ontario (CCO)...
Interim Phase I/II Clinical Trial Data for VAL-083 Show Clinical Activity in Refractory Glioblastoma
Interim phase I/II clinical trial data for VAL-083—a bifunctional DNA alkylator that crosses the blood-brain barrier with preferential accumulation in brain tumor tissue—in patients with recurrent glioblastoma multiforme were presented by Shih et al at the 4th Quadrennial Meeting of the ...
Further Improvement Needed in Breast MRI Use in Community Practice
In a study reported in JAMA Internal Medicine, Wernli et al evaluated use of breast magnetic resonance imaging (MRI) in the community setting from 2005 to 2009. They found that although recommended use of MRI for screening of high-risk women is increasing, considerable progress is needed in...
Increase in Breast MRIs Does Not Reflect Recommendations for Appropriate Use
In a study reported in JAMA Internal Medicine, Stout et al assessed use of breast magnetic resonance imaging (MRI) in the community setting from 2000 to 2011. They found a steep increase in use in screening and surveillance, with most women not meeting American Cancer Society (ACS) criteria for...
Epigenetic Modification of HAND2 May Be Associated With the Development of Endometrial Cancer
In a study reported in the journal PLoS One, Allison Jones, MD, of the Elizabeth Garrett Anderson Institute for Women’s Health, University College London, and colleagues analyzed the functional role of epigenetic factors in endometrial cancer development. They found that HAND2 methylation...
Study Finds Possible Link Between Allergies and Increased Risk of Hematologic Cancers in Women
A team of researchers looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies—in particular to plants, grass, and trees—with risk of blood cancers in women. The same association was not found in men, suggesting a possible...
12-Gene Recurrence Score Independently Predicts Recurrence in Patients With Stage II/III Colon Cancer
In a study reported in Journal of Clinical Oncology, Greg Yothers, PhD, of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Biostatistical Center and the University of Pittsburgh Graduate School of Public Health, and colleagues assessed performance of the 12-gene colon cancer...
Smoking Increases Risk of Death for Nasopharyngeal Carcinoma Survivors
Survivors of nasopharyngeal carcinoma who are former or current smokers are more likely to have their disease progress, relapse, or spread, and are more likely to die of their disease, compared with survivors of nasopharyngeal carcinoma who have never smoked, according to a study published in...
Studies Reveal Multiple Gene Alterations Responsible for Drug Resistance in BRAF-Mutated Melanoma
Two studies using whole-exome sequencing of treatment-resistant BRAF-mutated melanomas have identified multiple gene alterations, mostly affecting the MAPK pathway. Molecularly profiling BRAF-mutated melanoma patients at the time of resistance may improve their care by tailoring combinations of...
Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...
Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia
Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...
Predictors of Sentinel Lymph Node Metastasis Identified in Thin Melanomas
In a study reported in the Journal of Clinical Oncology, Dale Han, MD, of Moffitt Cancer Center, and colleagues in the Sentinel Lymph Node Working Group attempted to identify factors predictive of sentinel lymph node metastasis in thin melanomas. They found that Breslow thickness ≥ 0.75 mm, ...
STAT3 Activation Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
In a study reported in the Journal of Clinical Oncology, Xin Huang, PhD, of the National Clinical Research Center of Cancer in Tianjin, and colleagues investigated whether STAT3 activation can identify patients with diffuse large B-cell lymphoma treated with R-CHOP (rituximab [Rituxan] plus...
No Advantage of Concurrent vs Sequential Trastuzumab/Anthracycline Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
In the phase III Z1041 trial reported in The Lancet Oncology, Aman U. Buzdar, MD, of The University of Texas MD Anderson Cancer Center, and colleagues compared neoadjuvant therapy with FEC-75 (fluorouracil [5-FU], epirubicin, and cyclophosphamide) followed by paclitaxel plus trastuzumab (Herceptin) ...
Prognostic Model Predicts Metastatic Castration-Resistant Prostate Cancer Survival in Second-Line Chemotherapy After Docetaxel
In a study reported in the Journal of the National Cancer Institute, Susan Halabi, MD, of Duke University Medical Center, and colleagues developed and validated a prognostic model predicting prostate cancer survival in patients receiving second-line chemotherapy for castration-resistant...
Alternate VEGF Ligands Associated With Bevacizumab Resistance in Metastatic Colorectal Cancer
Results from a University of Colorado Cancer Center study indicated that bevacizumab (Avastin) resistance in patients with colorectal cancer may be due to increases in growth factors other than the targeted VEGF-A. The study, led by Christopher Lieu, MD, and published in the journal PLoS One,...
Timing and Choice of Treatment May Affect the Quality of Life of Young Breast Cancer Survivors
The choice and timing of therapeutic interventions may significantly affect the quality of life of young breast cancer survivors in the short term, although other quality-of-life domains such as family relationships may not be negatively impacted after treatment. These findings were reported by...
No Benefit From Adding Cetuximab to Pemetrexed in Recurrent/Progressive NSCLC After Platinum-Based Therapy
In a phase III trial reported in The Lancet Oncology, Edward S. Kim, MD, of Levine Cancer Institute, Carolinas HealthCare System, and colleagues investigated whether the addition of cetuximab (Erbitux) to pemetrexed (Alimta) improved progression-free survival in patients with recurrent or...
